A global phase 3 trial led by Mass General Brigham demonstrated that romiplostim reduces rates of chemotherapy‑induced thrombocytopenia (CIT) in patients receiving cytotoxic regimens. The study reported statistically and clinically meaningful reductions in severe thrombocytopenia and associated bleeding, enabling more patients to maintain planned chemotherapy dosing and schedules. Results were presented as a potentially practice‑changing dataset for supportive oncology care. Investigators noted improved platelet nadirs and fewer platelet transfusions in romiplostim‑treated arms, with safety data consistent with the drug’s established profile in other indications. Sponsors and oncology clinics will assess how romiplostim could integrate into standard anti‑neoplastic care, including cost, timing relative to multiple chemotherapy regimens, and impact on clinical outcomes such as progression‑free survival where treatment continuity matters.